Our Pipeline
Gandeeva’s proprietary platform leverages artificial intelligence, machine learning, and high-resolution molecular imaging to enable our team to predict and drug transient protein-protein interactions for therapeutic benefit. Our strategy allows us to discover drugs against previously inaccessible targets in oncology with unmet medical needs.
Discovery & Optimization
IND-Enabling
Phase 1/2
GND-323
Inhibitory molecular glue
Oncology - solid tumors
Discovery
IND-Enabling
Phase 1/2
GND-135
Small-molecule inhibitor
Rare diseases
Discovery
IND-Enabling
Phase 1/2
GND-02
Inhibitory molecular glue
Oncology - liquid tumors
Discovery
IND-Enabling
Phase 1/2
GND-03
Inhibitory molecular glue
Oncology - solid tumors
Discovery
IND-Enabling
Phase 1/2
iGluesTM
Gandeeva’s groundbreaking pipeline for iGluesTM leverages our AI-cryo-EM platform to identify and evaluate druggable interfaces, discover hits that bind to relevant interfaces followed by rapid, structure-guided, iterative hit-to-lead optimization.
Partnering
Our mission is to transform the lives of patients through the development of highly targeted, first-in-class therapeutics. We are open to the exploration of opportunities to expand our programs, from in-house development to collaborative research, and invite potential partners to contact us.
